Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.091 AUD | 0.00% | +1.11% | +31.88% |
Apr. 17 | Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint | MT |
Apr. 17 | Neurotech International Completes AU$10 Million Capital Raise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
+31.88% | 61.22M | |
-4.07% | 3.2B | |
-5.53% | 170M | |
-14.17% | 84.67M |
- Stock Market
- Equities
- NTI Stock
- News Neurotech International Limited
- Neurotech International Says Considerable Improvement in ASD Patients Treated with NTI164; Shares Decline 9%